Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 23 Neoplasms 12 Lymphoma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Neuroblastoma 3 Solid Tumors 2 Recurrence 2 Neoplasm Metastasis 2 Lymphoma, Non-Hodgkin 2 Glioma 2 Glioblastoma 2 Brain Neoplasms 2 Thromboembolism 1 Ovarian Neoplasms 1 Oligodendroglioma 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Follicular 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Granulosa Cell Tumor 1 Genetic Diseases, Inborn 1 Castration-resistant Prostate Cancer 1 Carcinoma 1 Breast Neoplasms 1 Astrocytoma 1 Advanced Cancer 1

Interventions

Nivolumab 20 Ipilimumab 10 Surveys and Questionnaires 7 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Interviews as Topic 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Cancer × Ketoconazole × Clear all

NCT00708591 2014-01-17

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

University of Chicago

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡